Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive database study probes link between popular diabetes drugs and rare thyroid cancer

NCT ID NCT07713901

Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study uses health records from millions of people to see if GLP-1 receptor agonists (drugs for type 2 diabetes and weight loss) are linked to a higher risk of medullary thyroid carcinoma, a rare cancer. Researchers will compare how often this cancer occurs in people taking GLP-1 RAs versus those on other treatments. The goal is to provide clearer safety information about these widely used medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study finds no link, it could reassure millions of people using GLP-1 RAs for diabetes or weight management.
What could go wrong
This is an observational study, not a controlled trial, so it can only show associations, not cause and effect. The rare cancer is very uncommon, making it hard to draw firm conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 93,600,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adults aged 18 years and older in the United States who are receiving routine treatment for type 2 diabetes or weight management and are identified utilizing real-world data (RWD).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older during the year of index (date of qualifying medication) * In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1 * ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period) * No evidence of cohort qualifying medication during 12-month before the index date * Reside in the US, including the District of Columbia (DC) during the study period * No missing values for year of birth Exclusion Criteria: * Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medullary thyroid carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary familial medullary thyroid carcinoma type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medullary thyroid carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IQVIA

    Parsippany, New Jersey, 07054, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.